首页> 外文期刊>Journal of Neurology, Neurosurgery and Psychiatry >Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
【24h】

Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.

机译:左旋多巴对帕金森病伴或不伴痴呆和路易小体痴呆患者认知功能的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Levodopa (L-dopa) is the gold standard treatment for Parkinson's disease, but a lack of clear efficacy combined with a perceived liability to neuropsychiatric side effects has limited L-dopa use in patients with parkinsonism and dementia. Therefore, the effect of L-dopa on the cognitive profile of dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) is unclear. AIM: To ascertain the acute and long-term effects of L-dopa on aspects of attention and cognition in patients with DLB and PDD, and to compare these with the effects in Parkinson's disease. METHOD: Baseline cognitive and motor function was assessed off L-dopa in patients with Parkinson's disease (n = 22), PDD (n = 27) and DLB (n = 11) using standard "bedside" measures and a computerised programme detecting reaction times and accuracy. All patients then underwent an acute L-dopa challenge with subsequent subjective and objective analysis of alertness, verbal recall, reaction times and accuracy. The same parameters were measured after 3 months on L-dopa to assess the prolonged effect. RESULTS: Acute L-dopa challenge considerably improved motor function and subjective alertness in all patients without compromising either reaction times or accuracy, but increased fluctuations were noted in both groups with dementia. Neuropsychiatric scores improved in patients with Parkinson's disease both with and without dementia on L-dopa at 3 months. Although patients with Parkinson's disease also had better mean global cognitive function at this time, mean verbal attention and memory deteriorated, and patients with PDD had slower reaction times in some tests. No patient had a marked deterioration over this time. Patients with DLB did not experience any adverse cognitive or neuropsychiatric effects after 3 months of L-dopa treatment. CONCLUSION: The use of L-dopa in patients with parkinsonism with dementia does not adversely affect cognitive function.
机译:背景:左旋多巴(左旋多巴)是帕金森氏病的金标准治疗方法,但是缺乏明确的疗效以及对神经精神副作用的公认责任限制了左旋多巴在帕金森氏症和痴呆症患者中的使用。因此,尚不清楚左旋多巴对路易小体痴呆(DLB)和帕金森病痴呆(PDD)认知状况的影响。目的:确定左旋多巴对DLB和PDD患者注意和认知方面的急性和长期影响,并将其与帕金森氏病的影响进行比较。方法:采用标准的“床旁”措施和计算机程序检测反应时间,评估帕金森病(n = 22),PDD(n = 27)和DLB(n = 11)患者左旋多巴的基线认知和运动功能和准确性。然后,所有患者均接受急性左旋多巴攻击,随后对警报,口头回忆,反应时间和准确性进行主观和客观分析。 3个月后在左旋多巴上测量相同的参数以评估延长的作用。结果:急性左旋多巴的挑战大大改善了所有患者的运动功能和主观警觉性,而没有影响反应时间或准确性,但两组痴呆症患者的波动均增加。帕金森氏病伴或不伴痴呆的L-多巴患者在3个月时的神经精神学评分均得到改善。尽管此时帕金森氏病患者的平均总体认知功能也更好,但平均言语注意力和记忆力却有所下降,PDD患者在某些测试中的反应时间较慢。在这段时间内,没有患者有明显的恶化。 L-多巴治疗3个月后,DLB患者未出现任何不良的认知或神经精神疾病。结论:帕金森病伴痴呆患者使用左旋多巴不会对认知功能产生不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号